Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (NYSE: LH) announced a quarterly cash dividend of $0.72 per share. The dividend is payable on March 12, 2026 to shareholders of record at the close of business on February 27, 2026.
Labcorp (NYSE: LH) expanded its Labcorp Plasma Detect molecular residual disease (MRD) portfolio on Jan 13, 2026, adding Plasma Detect ID for stage I–III breast cancer and stage I–IIIA non-small cell lung cancer and nationwide availability of Plasma Detect Genome for stage III colon cancer.
Both tests report a limit of detection (LOD95) of 0.005% for circulating tumor DNA (ctDNA). The company cited recurrence rates ranging from 10%–55% for NSCLC, 10%–40% for breast cancer, and about 35% for stage III colon cancer, and noted peer-reviewed studies and AMP 2025 data supporting clinical utility.
Visby Medical (LH) expanded consumer access to its FDA-authorized at-home Women’s Sexual Health Test, a palm-sized PCR device delivering lab-quality results in ~30 minutes for chlamydia, gonorrhea, and trichomoniasis. As of November 2025 the test is purchasable on questhealth.com, and it is now available on Labcorp OnDemand; Ovia Health by Labcorp plans employer/health-plan distribution in early 2026. The test enables a self-collected vaginal swab, secure app results, and links to same-day virtual care and medication via third-party providers, aiming to reduce testing delays and untreated STI complications.
NAMSA (ARCHIMED portfolio) completed the acquisition of the U.S. assets of Labcorp's Early Development medical device testing business on Jan 8, 2026, expanding NAMSA's U.S. service portfolio to include biocompatibility, microbiological, analytical testing and preclinical research.
The deal positions NAMSA as a broader end-to-end MedTech testing partner, transfers Labcorp Early Development device projects to NAMSA facilities in Ohio, Minnesota, Georgia and California, and is NAMSA's 10th acquisition since joining ARCHIMED in 2020.
Labcorp (NYSE: LH) will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT. A live audio webcast will be available on the company investor relations site ir.Labcorp.com and will be archived for replay.
The presentation offers investors and analysts direct access to management commentary on strategy and market outlook; no financial results or guidance are included in this announcement.
Labcorp (NYSE: LH) completed the acquisition of select ambulatory outreach laboratory assets from Community Health Systems subsidiary CHS for approximately $194 million in cash on December 2, 2025.
The sale covers outreach lab services, certain patient service centers and in‑office phlebotomy locations in 13 states. CHS will continue to operate inpatient and emergency department laboratories and hospital-based lab services. Labcorp said the transaction expands access to its specialty testing menu, data analytics and digital tools for CHS‑affiliated patients and providers.
Labcorp (NYSE: LH) announced the appointment of Victor Bulto to its Board of Directors, effective December 1, 2025. Bulto currently leads Novartis' U.S. business, a $20+ billion operation, and brings 25 years of global healthcare leadership across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.
Labcorp highlighted his experience in transformation, technology and automation, and commercial strategy as supportive of its long-term growth priorities in precision medicine, patient access to novel therapies, and innovation through science and technology.
Labcorp (NYSE: LH) announced that Labcorp Plasma Detect, a tumor‑informed blood assay for detecting molecular residual disease (MRD) from circulating tumor DNA, was featured in two peer‑reviewed studies published Nov 19, 2025.
A Nature Medicine study in diffuse pleural mesothelioma reported that both neoadjuvant immune regimens were safe, enabled most patients to undergo surgery, and that Plasma Detect tracked early disease progression and predicted long‑term progression‑free survival. A Clinical Cancer Research study found that lymph drain fluid collected 24 hours after head and neck cancer surgery contained more tumor DNA than simultaneous plasma and that lymph‑based testing identified residual cancer missed by pathology.
Labcorp (NYSE: LH) reported third-quarter 2025 results with revenue $3.56B (up 8.6% YoY) and diluted EPS $3.12 versus $2.00 a year ago. Adjusted EPS was $4.18 (up 19.4% YoY). Operating income margin improved to 11.1% and free cash flow for the quarter was $280.5M.
The company updated 2025 guidance: enterprise revenue growth of 7.4%–8.0% (midpoint lowered ~40 bps), adjusted EPS $16.15–$16.50 (midpoint +$0.05) and free cash flow $1.17B–$1.29B (midpoint +$25M). Labcorp announced multiple asset acquisitions, a $0.72 quarterly dividend and $25M of share repurchases in the quarter.
Labcorp (NYSE: LH) will offer Roche's FDA-cleared Elecsys pTau181 blood test nationwide by early 2026 to aid initial assessment of Alzheimer's-related amyloid pathology in primary care. The test is intended for adults 55+ with cognitive complaints and measures plasma phosphorylated Tau 181. Roche reported a 97.9% negative predictive value (NPV), meaning a negative result aligns with a negative amyloid PET and lowers the likelihood that cognitive impairment is due to amyloid pathology. Testing can be performed at a clinician's office or at any of Labcorp's >2,200 patient service centers.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
